S-adenosyl-l-methionine overcomes ul3-mediated drug resistance in p53 deleted colon cancer cells

30Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

Purpose: In order to study novel therapeutic approaches taking advantage of natural compounds showing anticancer and anti-proliferative effects, we focused our interest on S-adenosylL-methionine, a naturally occurring sulfur-containing nucleoside synthesized from adenosine triphosphate and methionine by methionine adenosyltransferase, and its potential in overcoming drug resistance in colon cancer cells devoid of p53. Results: In the present study, we demonstrated that S-adenosyl-L-methionine overcomes uL3-mediated drug resistance in p53 deleted colon cancer cells. In particular, we demonstrated that S-adenosyl-L-methionine causes cell cycle arrest at the S phase; inhibits autophagy; augments reactive oxygen species; and induces apoptosis in these cancer cells. Conclusions: Results reported in this paper led us to propose S-adenosyl-L-methionine as a potential promising agent for cancer therapy by examining p53 and uL3 profiles in tumors to yield a better clinical outcomes.

Cite

CITATION STYLE

APA

Mosca, L., Pagano, M., Pecoraro, A., Borzacchiello, L., Mele, L., Cacciapuoti, G., … Russo, A. (2021). S-adenosyl-l-methionine overcomes ul3-mediated drug resistance in p53 deleted colon cancer cells. International Journal of Molecular Sciences, 22(1), 1–18. https://doi.org/10.3390/ijms22010103

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free